Bone Biologics Corporation (BBLG)
NASDAQ: BBLG · Real-Time Price · USD
1.320
+0.130 (10.92%)
At close: Nov 19, 2024, 4:00 PM
1.300
-0.020 (-1.51%)
After-hours: Nov 19, 2024, 5:56 PM EST

Bone Biologics Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Bone Biologics.

Analyst Consensus: n/a
Target Low Average Median High
Price n/a n/a n/a n/a
Change n/a n/a n/a n/a

Analyst Ratings

There are currently no analyst ratings available for Bone Biologics.

Recommendation Trends

Rating Jan '23Feb '23Mar '23Apr '23
Strong Buy 1110
Buy 0000
Hold 0000
Sell 0000
Strong Sell 0000
Total 1110

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
EF Hutton
EF Hutton
Strong Buy
Reiterates
$540
Strong Buy Reiterates $540 +40,809.09% Apr 13, 2023
EF Hutton
EF Hutton
Strong Buy
Reiterates
$540
Strong Buy Reiterates $540 +40,809.09% Apr 3, 2023
EF Hutton
EF Hutton
Strong Buy
Initiates
$540
Strong Buy Initiates $540 +40,809.09% Oct 18, 2022
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.23
from -34.01
EPS Next Year
-2.23
from -3.23
Fiscal Year FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Period Ending Dec 31, 2019 Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026
Revenue
--------
Revenue Growth
--------
EPS
-66.97-35.68-37.35-31.15-34.01-3.23-2.23-2.25
EPS Growth
--------
Forward PE
--------
No. Analysts -----333
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202420252026
High n/a n/a n/a
Avg n/a n/a n/a
Low n/a n/a n/a

Revenue Growth

Revenue Growth 202420252026
High - - -
Avg - - -
Low - - -

EPS Forecast

EPS 202420252026
High -3.33 -2.30 -2.32
Avg -3.23 -2.23 -2.25
Low -3.11 -2.15 -2.17

EPS Growth

EPS Growth 202420252026
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.